It is the first orally administered therapy for the treatment of two types of ANCA-associated vasculitis approved in Japan
As part of this strategic partnership, LTI with its digital, technical and life sciences domain capabilities, will help accelerate joint go-to-market pursuits and faster deployment for Clinpal Adopters
The company operates in over eight cities and the start-up plans to expand its reach to over 100 non-metro cities in the next 18-24 months
The company plans to launch its exclusive e-pharmacy and telemedicine services in India by December 2021
saRNA is a new platform for the development of medicines and vaccines which uses similar technology to mRNA but with the added ability to self-amplify, thereby expressing proteins for longer, resulting in higher protein levels per dose level
CuraTeQ Biologics is on track for filing a second oncology biosimilar
These modules will act as a guide to doctors and health care workers to deal with post-Covid-19 issues
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
In participants 5 to 11 years of age, the vaccine was safe, well-tolerated and showed robust neutralising antibody responses. Results in children under 5 years of age are expected as soon as later this year
Subscribe To Our Newsletter & Stay Updated
